Skip to main content
IXICO PLC logo

IXICO PLC — Investor Relations & Filings

Ticker · IXI ISIN · GB00BFXR4C20 LEI · 2138005M1F59O6HWSA97 IL Professional, scientific and technical activities
Open in API
Filings indexed 354 across all filing types
Latest filing 2016-11-16 Regulatory Filings
Country GB United Kingdom
Listing IL IXI

About IXICO PLC

https://www.ixico.com/

IXICO PLC is a clinical research and data analytics company specializing in neuroscience. It provides neuroimaging and digital biomarker analytics to biopharmaceutical firms conducting clinical trials for neurological disorders. The company utilizes its proprietary, AI-driven technology platform to manage and analyze complex imaging and digital health data. This platform deploys disease-specific algorithms to generate reliable clinical data and precision insights, aiming to accelerate research and development decision-making, de-risk clinical studies, and support the advancement of new therapies for conditions such as Alzheimer's and Huntington's disease.

Recent filings

Filing Released Lang Actions
Participation in major EU partnership (ROADMAP)
Regulatory Filings Classification · 1% confidence The document begins with 'RNS Number : 2693P' and is dated 16 November 2016. The content describes a specific business development—receiving funding for a research project—and concludes with 'This information is provided by RNS The company news service from the London Stock Exchange END'. This structure is characteristic of a general regulatory announcement disseminated via the Regulatory News Service (RNS). Since the content is a specific announcement (not a full report like 10-K or IR, nor a proxy statement or earnings release), and it is explicitly marked as an RNS filing, the most appropriate classification is RNS.
2016-11-16 English
Pre-Close Trading Update
Regulatory Filings Classification · 1% confidence The document is identified by the 'RNS Number' header and the 'END' marker typical of London Stock Exchange regulatory news service releases. The content is a 'Pre-Close Trading Update' providing summary financial figures (£3.1 million revenue, net cash position) for the year ended 30 September 2016, and it explicitly states that the 'audited results to 30 September 2016 will be announced in December 2016.' Since this is a preliminary update announcing financial performance ahead of the full results, it aligns best with an Earnings Release (ER), which covers initial announcements of periodical financial results (key highlights only). It is not the full Annual Report (10-K) or the comprehensive Interim Report (IR), but rather a pre-close trading statement. Given the context of providing key financial highlights before the official results, ER is the most appropriate classification.
2016-10-21 English
$1.2m contract with new global pharma customer
Regulatory Filings Classification · 1% confidence The document begins with an 'RNS Number' and is dated, indicating it is a regulatory announcement. The content describes a significant business event: signing a new contract worth US$1.2m with a pharmaceutical company for clinical trial services. This type of material announcement, which details business developments, contract wins, or operational updates that are not strictly financial results (ER), management changes (MANG), or capital structure changes (CAP), typically falls under general regulatory announcements. Since it is a specific news item released via the RNS service and doesn't fit the definitions for ER, CT, MANG, or others, the most appropriate classification is the general regulatory filing category, RNS. The document length (4939 chars) is substantial enough that it is the primary announcement itself, not just a notice about an attachment (which would suggest RPA).
2016-10-20 English
EUR1m funding as a partner in major EU consortium
Regulatory Filings Classification · 1% confidence The document begins with an 'RNS Number' and is dated October 10, 2016. It announces that IXICO plc will receive €1 million in funding as a partner in a major EU public-private consortium (AMYPAD) related to Alzheimer's Disease diagnostics. This is a specific corporate announcement regarding a partnership, funding, and technology deployment. It is not a full annual report (10-K), an earnings release (ER), or a quarterly report (IR). It details a specific business development and potential revenue opportunity. Since it is a formal announcement disseminated via the RNS system, and it describes a significant business event rather than a routine financial filing or a report itself, it fits best under the general 'Regulatory Filings' category (RNS) as a specific corporate news item, although it could also be argued as a 'Capital/Financing Update' (CAP) due to the €1m funding. However, the primary focus is the announcement of participation in a consortium, which is typical for RNS announcements that don't fit other specific categories like DIV or DIRS. Given the context of being disseminated via RNS and detailing a strategic partnership/funding, RNS is the most appropriate general regulatory announcement code.
2016-10-10 English
Appointment of Shore Capital as Nominated Adviser
Regulatory Filings Classification · 1% confidence The document is very short (1988 characters) and announces a specific corporate action: the appointment of a new Nominated Adviser and Sole Broker (Shore Capital). It is disseminated via the 'RNS Number' system, which is the London Stock Exchange's news service. This type of announcement, which is a specific corporate update that doesn't fit into standard financial reports (10-K, IR, ER) or specific corporate actions like dividends or share buybacks, is best classified as a general regulatory announcement or filing. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback category for miscellaneous, time-sensitive regulatory news disseminated through the official news service, especially since it is not a report itself but an announcement of an administrative/advisory change.
2016-10-03 English
Appointment of Shore Capital
Regulatory Filings Classification · 1% confidence The document is identified by the header 'RNS Number : 2404L' and explicitly states 'This information is provided by RNS The company news service from the London Stock Exchange'. The content announces the 'Appointment of Shore Capital as Nominated Adviser & Sole Broker'. This is a general regulatory announcement concerning corporate advisory roles, which does not fit into specific categories like Director's Dealing (DIRS), Capital Change (CAP), or Dividend (DIV). Therefore, it falls best under the general regulatory announcement category, RNS.
2016-10-03 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.